Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measuring the impact of an educational intervention in rheumatoid arthritis: An open-label, randomized trial.
Michou L, Julien AS, Witteman HO, Légaré J, Ratelle L, Godbout A, Tardif J, Côté S, Boily G, Lui R, Ikic A, Trudeau J, Tremblay JL, Fortin I, Bessette L, Chetaille AL, Fortin PR. Michou L, et al. Among authors: fortin i. Arch Rheumatol. 2021 Dec 24;37(2):169-179. doi: 10.46497/ArchRheumatol.2022.8965. eCollection 2022 Jun. Arch Rheumatol. 2021. PMID: 36017212 Free PMC article.
Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.
Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, Haaland D, Elmoufti S, Staelens F, Bogatyreva I, Syrotuik J, Shaikh S. Bessette L, et al. Among authors: fortin i. Ther Adv Musculoskelet Dis. 2019 Mar 5;11:1759720X19831151. doi: 10.1177/1759720X19831151. eCollection 2019. Ther Adv Musculoskelet Dis. 2019. PMID: 30858896 Free PMC article.
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Haraoui B, Khraishi M, Choquette D, Lisnevskaia L, Teo M, Kinch C, Galos C, Roy P, Gruben D, Woolcott JC, Vaillancourt J, Sampalis JS, Keystone EC; Canadian Tofacitinib for Rheumatoid Arthritis Observational Investigators. Haraoui B, et al. Arthritis Care Res (Hoboken). 2023 Feb;75(2):240-251. doi: 10.1002/acr.24966. Epub 2022 Oct 10. Arthritis Care Res (Hoboken). 2023. PMID: 35678771 Free PMC article.
Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S. Touma Z, et al. Among authors: fortin i. Rheumatol Int. 2017 Jun;37(6):865-873. doi: 10.1007/s00296-017-3682-9. Epub 2017 Mar 9. Rheumatol Int. 2017. PMID: 28280970 Free PMC article.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R; TULIP-2 Trial Investigators. Morand EF, et al. N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. N Engl J Med. 2020. PMID: 31851795 Clinical Trial.
The patient advisor, an organizational resource as a lever for an enhanced oncology patient experience (PAROLE-onco): a longitudinal multiple case study protocol.
Pomey MP, de Guise M, Desforges M, Bouchard K, Vialaron C, Normandin L, Iliescu-Nelea M, Fortin I, Ganache I, Régis C, Rosberger Z, Charpentier D, Bélanger L, Dorval M, Ghadiri DP, Lavoie-Tremblay M, Boivin A, Pelletier JF, Fernandez N, Danino AM. Pomey MP, et al. Among authors: fortin i. BMC Health Serv Res. 2021 Jan 4;21(1):10. doi: 10.1186/s12913-020-06009-4. BMC Health Serv Res. 2021. PMID: 33397386 Free PMC article.
Correction to: The patient advisor, an organizational resource as a lever for an enhanced oncology patient experience (PAROLEonco): a longitudinal multiple case study protocol.
Pomey MP, de Guise M, Desforges M, Bouchard K, Vialaron C, Normandin L, Iliescu-Nelea M, Fortin I, Ganache I, Régis C, Rosberger Z, Charpentier D, Bélanger L, Dorval M, Ghadiri DP, Lavoie-Tremblay M, Boivin A, Pelletier JF, Fernandez N, Danino AM. Pomey MP, et al. Among authors: fortin i. BMC Health Serv Res. 2021 Jan 14;21(1):67. doi: 10.1186/s12913-021-06065-4. BMC Health Serv Res. 2021. PMID: 33446153 Free PMC article. No abstract available.
34 results